PolyVascular

About PolyVascular

PolyVascular Inc. is dedicated to improving the lives of children with congenital heart defects by providing innovative, minimally invasive heart valve solutions. Their mission is to reduce the need for open-heart surgeries, enabling children as young as 2 years old to lead healthy, normal lives.

Products & Services

Transcatheter Pulmonary Valve:A non-surgical pulmonary valve and delivery system designed for children as young as 2 years old, reducing the need for open-heart surgery with a biocompatible, durable, polymer-based valve.

Specialties

Pediatric Cardiology Transcatheter Heart Valves Minimally Invasive Medical Devices

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2023-08-29 FD: 2023-08-29	1 investors

Grant Latest

2023-08-29

$2.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

W

Will Clifton

Operational & Clinical Consultant

C

Cindy Clague

VP of Research & Development

K

Kelly McKinzey

Engineering Manager

L

Larry Scott

Product Development Engineer

D

Doug Smith

Controller

K

Katie Bales

VP, Investor Relations

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

PolyVascular Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised